Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is RIVAROXABAN USP MICRONIZED, with a corresponding US DMF Number 28816.
Remarkably, this DMF maintains an Active status since its submission on March 06, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 16, 2015, and payment made on March 05, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II